Clinical Trial Update: A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of L-DOS47 in patients with recurrent or metastatic non-squamous non-small cell lung cancer was terminated; results were posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• L-DOS47

Snippet

Sponsor: Helix BioPharma Corporation | Conditions: Non-Small Cell Lung Cancer | Phase 1 | Status: TERMINATED | Results posted: 2024-06-03